{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-267038","form_type":"8-K","ticker":"CPRX","cik":"0001369568","company_name":"CATALYST PHARMACEUTICALS, INC.","filed_at":"2025-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.241608+00:00","generated_at":"2026-05-17T00:13:05.717009+00:00","sec_items":["8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Catalyst Pharma Q3 rev $148.4M (+17% YoY); raises FY25 revenue guidance to $565-$585M","bullets":["GAAP net income $52.8M ($0.42 diluted EPS); non-GAAP net income $86.1M ($0.68 diluted EPS).","FIRDAPSE net revenue $92.2M (+16.2% YoY); AGAMREE net revenue $32.4M (+115.2% YoY).","FYCOMPA net revenue $23.8M (-25.8% YoY) as first generic tablet entered market in Q2 2025.","Cash and equivalents $689.9M as of Sep 30, 2025; $200M share repurchase program announced.","Full-year AGAMREE guidance raised to $105-$115M; FYCOMPA guidance raised to $100-$110M."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-267038","json":"https://secwatch.observer/filing/0001193125-25-267038.json","markdown":"https://secwatch.observer/filing/0001193125-25-267038.md","text":"https://secwatch.observer/filing/0001193125-25-267038.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1369568/000119312525267038/0001193125-25-267038-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1369568/000119312525267038/d56925d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:13:05.717009+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}